Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.

UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.

The U.S. Food and Drug Administration (FDA) has granted emergency use for two new coronavirus vaccines, one developed by the drug company Pfizer and the biotech company BioNTech and the other by the biotech company ModernaTX. Both are mRNA vaccines and have similar structure.

Both vaccines contain modified mRNA that provides the instructions for the synthesis of the SARS-CoV-2 spike glycoprotein antigen. Its mRNA is enveloped in lipid nanoparticles (LNPs) to prevent degradation and enhance uptake into cells.

By Jacqueline Howard and Jen Christensen, CNN

(CNN)Vaccine advisers to the US Centers for Disease Control and Prevention voted 13-1 on Sunday to recommend that both older adults, ages 75 and older, and "frontline essential workers" including first responders be next in line to receive Covid-19 vaccines.

That would put those people in "Phase 1b" of allocating the vaccine nationwide.

The December 2020 issue of Health Affairs is the first-ever focused exclusively on the intersection of climate and health. It covers topics including the health sector’s contribution to carbon emissions and other forms of pollution, how communities are affected by and adapting to the changing climate, and policies to protect against further damage. Kristie Ebi, UW CHanGE, served as theme adviser of the issue.